Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice.
In order to understand better the origins of the elevated levels of the glycoform of IgG that lacks galactose on both arms of the oligosaccharide chain (G0%) located in the Fc, which occurs in man and mouse with age, and in particular in autoimmune disease, we investigated the clearance of two glycosylated forms of IgG2a and IgG1 in normal (BALB/c) and autoimmune-prone (MRL/1pr, MRL/+, and non-obese diabetic (NOD)) mice. To investigate the possibility of different rates of catabolism, enzymatically generated glycoforms of monomeric IgG1 and IgG2a (fully glycosylated or G0%), were iodinated and injected into the tail vein of the mice. We found that the G0% IgG2a remained in circulation significantly longer than the fully glycosylated variants, in all of the mouse strains tested. In contrast, the two forms of IgG1 had similar kinetics in all the autoimmune-prone mice, whereas in BALB/c, there was a longer half-life (t1/2) for G0% IgG1. These data suggest that there may be differences in the ability of the IgG glycoforms to bind to the Fc gamma receptors, in particular Fc gamma RI. The clearance rates were found to vary among the strains studied, with MRL/1pr having the fastest catabolic rates for all glycoforms and IgG subclasses tested. This appeared to be due to the presence of circulating IgG and IgM rheumatoid factors (RF). There were significantly increased frequencies and titres for both IgM and IgG RF in MRL/1pr mice compared with the other strains. In contrast, interferon-gamma, known to induce the Fc gamma RI, was found to be similar in the sera, in all of the strains of mice examined. These results suggest that RF probably play an important biological function in the MRL/1pr mice and aid in the clearance of circulating IgG. Our study shows that the state of glycosylation of IgG affects the t1/2 in vivo, and that by removing the terminal sugars (sialic acid and galactose), the antibody (IgG2a) will remain in circulation significantly longer. These observations may thus provide a partial explanation for the increase in relative percentage of this glycoform that occurs with age.
Newkirk
M M
MM
Department of Medicine, McGill University, Montreal General Hospital Research Institute, Quebec, Canada.
Novick
J
J
Stevenson
M M
MM
Fournier
M J
MJ
Apostolakos
P
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism; D005260:Female; D005690:Galactose / Q000493:pharmacokinetics*; D006031:Glycosylation; D006207:Half-Life; D007074:Immunoglobulin G / Q000145:classification / Q000378:metabolism*; D007700:Kinetics; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D019463:Mice, Inbred MRL lpr; D016688:Mice, Inbred NOD; D019158:N-Acetylneuraminic Acid / Q000493:pharmacokinetics; D017452:Receptors, IgG / Q000378:metabolism; D012217:Rheumatoid Factor / Q000502:physiology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D017452:Receptors, IgG; D012217:Rheumatoid Factor; D019158:N-Acetylneuraminic Acid; D005690:Galactose